First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.

Cancer Rep (Hoboken) · 2021 · PMC8714542 · PMID 34137219

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

While our results are highly significant and strongly support the use of immunotherapy in the 1L setting, the data were evaluated retrospectively and there are several limitations to this type of analysis.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.